Pain Therapeutics (PTIE) Earns Daily Media Impact Rating of 0.19

News stories about Pain Therapeutics (NASDAQ:PTIE) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pain Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 47.4016387665999 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Pain Therapeutics (NASDAQ:PTIE) traded down $0.20 during mid-day trading on Thursday, reaching $6.24. 47,458 shares of the company’s stock traded hands, compared to its average volume of 1,449,969. The firm has a market capitalization of $41.95, a P/E ratio of -3.43 and a beta of 2.83. Pain Therapeutics has a 1 year low of $3.10 and a 1 year high of $12.80.

Pain Therapeutics (NASDAQ:PTIE) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter. research analysts expect that Pain Therapeutics will post -2.5 earnings per share for the current year.

PTIE has been the subject of several research reports. ValuEngine downgraded shares of Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th.

COPYRIGHT VIOLATION WARNING: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit